Introduction
Bioisosterism is a common strategy for optimization of lead compounds in medicinal chemistry which involves structural modifications of bioactive compounds by replacement of functional groups or scaffolds. We have used the chromone and chroman-4-one ring systems as scaffolds for the development of potent and selective sirtuin 2 (SIRT2) enzyme inhibitors ( Fig. 1 ). 1, 2 Sirtuins (SIRTs) catalyze the deacylation of lysine residues on numerous protein substrates requiring NAD + as a co-substrate. 3, 4 The SIRT enzymes are considered to be important in various pathologies such as cancer, neurodegeneration, diabetes, inflammation and cardiovascular diseases and therefore, the development of SIRT inhibitor is of vast interest. [5] [6] [7] [8] [9] [10] Despite the synthetic efforts to develop potent inhibitors the majority of the reported inhibitors show IC 50 values in the submicromolar to micromolar range with only a handful of examples exibiting nanolar inhibitory activity. 9, 11 A drawback of the previously described chromone and chroman-4one based SIRT2 inhibitors (e.g. 1, Fig. 1 ) 1 was their high lipophilicity which prevented their use in more advanced biological assays as they precipitated at relevant test concentrations. Efforts to increase the hydrophilicity afforded compounds containing heterofunctional groups such as pyridyl or oxadiazole moieties (3 and 5, respectively, Fig. 1 ) that allowed them to be tested for their SIRT2-mediated antiproliferative effects in cancer cells. 2 To further improve the physicochemical properties of potential SIRT2 inhibitors we decided to investigate the effect of replacing the chroman-4-one scaffold with other heterocyclic frameworks (Scheme 1).
In the present study, a set of compounds based on three types of bicyclic scaffolds has been synthesized and evaluated for their activity as sirtuin inhibitors.
Quinolin-4(1H)-ones (A) and bicyclic secondary sulfonamides such as benzothiazine-1,1-dioxides (B) and benzothiadiazine-1,1-dioxides (C-D), or saccharins (E) are versatile scaffolds found in bioactive compounds. The quinolin-4(1H)-one is structurally similar to the chromone and is a common scaffold in antibacterial agents such as fluoroquinolones. 12 Benzothiadiazine-1,1-dioxide derivatives have been used as diuretic drugs since the 1950s and this scaffold is a frequent motif also in other biologically relevant substances. 13, 14 Saccharin, widely used as an artificial sweetener, has been successfully used as a core structure in e.g. inhibitors of carbonic anhydrases 15 and is also a key element of repinotan, a highly selective 5-HT 1A -receptor agonist. 16 The new scaffold analogues contained comparable substitution patterns to the previously studied chroman-4-ones/chromones. The observed structure-activity relationships (SAR) were in agreement with the findings from docking studies conducted with a SIRT2 3D model previously published. 2 
Results and discussion

Design
The design of new scaffold analogues was guided by SAR studies and the suggested binding mode achieved from molecular modelling trials performed around the parent chroman-4-one/chromone scaffold. 1, 2 The main focus was the replacement of the core structure with less lipophilic ring systems in order to improve the physicochemical properties. To elucidate the influence of the scaffold replacement on the inhibitory properties, we aimed to retain a characteristic substitution pattern which has proven to be vital for inhibitory activity of derivatives based on the chroman-4-one/chromone framework. Hence, the scaffolds should contain a hydrogen bond acceptor (HBA) group mimicking the carbonyl group thereby retaining the hydrogen bond to a structural water molecule. In addition, the introduction of functional groups in positions mimicking the 2-and 6-position of the chroman-4ones/chromones should be allowed (see Scheme 1 for numbering). The new compounds should preferably be brominated at the site corresponding to the 6-position of the parent scaffold since chroman-4-one derivatives holding a Br-substituent in this position showed higher inhibitory activity than other substituents due to a halogen bond interaction with a backbone carbonyl group of SIRT2. Introduction of an additional Br-group in the corresponding 8-position might be beneficial to increase the inhibitory activity even further due to hydrophobic interactions with the target protein. The substituent in the 2-position of the chroman-4-ones/chromones is located in a narrow hydrophobic tunnel pointing towards the surrounding water environment. Consequently, the group representing this substituent should be a linear aliphatic moiety which can be substituted with heterocycles and bulkier groups when separated from the core structure with at least an ethylene spacer. 1, 2 The heterocyclic frameworks shown in Scheme 1 emerged as promising alternatives as they are similar in size to the chroman-4-ones/ chromones, readily accessible by synthesis and can be substituted with functional groups in equivalent positions as the parent scaffold to maintain the key binding properties of known, potent SIRT2-selective inhibitors ( Fig. 1, 1-5 ). The calculated logP values of scaffolds B-E are significantly lower than the one of the chroman-4-one scaffold, indicating a good starting point for addressing the issues of the less favourable physicochemical properties exhibited by the chroman-4-one series. In addition, the quinolin-4-(1H)-one framework (A) was also considered to be of interest due to its structural similarities to the chromone scaffold despite its higher clogP-value.
Chemistry
The synthesis towards the quinolin-4-(1H)-one-based analogues is shown in Scheme 2. The scaffold was synthesized from β-ketoesters and anilines employing the Conrad-Limpach reaction. The β-ketoesters 8a-c were obtained in good yields by reacting monomethyl potassium malonate (6) with the CDI-activated carboxylic acids 7a-c in anhydrous THF at room temperature. 17 2-Bromo-4-chloroaniline was then reacted with 8a-c under argon at 50°C for 48 h to afford the intermediate enaminoesters 9a-c. After removal of excess aniline and p-toluenesulfonic acid (p-TSA) the cyclization was achieved by heating the enaminoesters to 250°C in diphenyl ether for 45 min using microwave heating. The quinolin-4-(1H)-ones 10a-c were finally isolated by crystallization from hexane.
Four analogues with the benzothiazine-1,1-dioxide scaffold were The key-binding interactions of the chroman-4-one based inhibitors with SIRT2 have been highlighted in 2. 2 T. Seifert, et al. Bioorganic & Medicinal Chemistry 28 (2020) 115231 synthesized as outlined in Scheme 3. 2-Aminobenzenesulfonamide (11) was reacted in a Sandmeyer-type reaction with NaNO 2 at 0°C followed by the addition of KI. Introduction of the bromide in the 5-position was pursued via the reaction of 12 with N-bromosuccinimide (NBS). Aryl iodides 12 and 13 were successfully used in a Sonogashira reaction yielding the precursor for the subsequent 6-endo-dig cyclization to afford the desired products 15a-d.
The synthesis of derivatives based on the benzothiadiazine-1,1-dioxide scaffolds is shown in Scheme 4. 2-Amino-3,5-dibromobenzenesulfonamide 11 was obtained by reacting 2-aminobenzene-sulfonamide with Br 2 in DMF at room temperature. Sulfonamide 16 was then either reacted with various aldehydes or carboxylic acids which defined the substituent in the 3-position and the degree of saturation of the scaffold. Aldehydes 17a and 17b employed in the aforementioned reaction were commercially available. Whereas, compound 17c was obtained via a reduction-oxidation protocol from 3-(3-bromophenyl)propionic acid (Supporting Information) and 17d, used to introduce the quinolin-2(1H)-one moiety in the 3-position of 18d, was synthesized in three steps as previously reported by our group. 2 The acid-catalyzed reaction of 16 with aldehydes 17a-d was carried out under microwave heating at 120°C in dioxane to afford 18a-d in 34-53% yield.
As outlined in Scheme 4, the unsaturated benzothiadiazine-1,1-dioxides 21a-c were synthesized via a reaction of CDI-activated carboxylic acids with 16 leading to amide intermediates 20a-c which were cyclized under microwave heating to afford 21a-c. 18 The synthesis of saccharin derivatives substituted in the 2-position is shown in Scheme 5. As earlier mentioned the SAR study of the chroman-4-ones revealed that halogen atoms in the 6-and 8-positions are essential for activity. Thus, dibrominated saccharins were considered promising derivatives. However, bromination of 2-methylbenzenesulfonamide by the previously used method (Br 2 in DMF) was unsuccessful. Attempts to obtain a dihalogenated precursor for saccharin synthesis via chlorosulfonation of 4-bromo-2-chlorotoluene yielded only the non-desired isomer, with the sulfonyl chloride moiety in the meta-position to the methyl group.
Instead, the mono-brominated derivative 23 was synthesized by chlorosulfonation of 4-bromotoluene (22) . The desired isomer 23 was obtained together with small amounts of the meta-substituted regioisomer (14-21%). The isomeric mixture was used in the following reaction converting 23 to the corresponding sulfonamide 24 with aqueous ammonia. A subsequent oxidation reaction, as reported by Xu et al. using H 5 IO 6 and sub-stoichiometric amounts of CrO 3 furnished 6-bromosaccharin (28) in 46% yield. 19 Alternatively, 28 was obtained in [1, 2] 62% overall yield via oxidative cyclization under similar conditions of N-tert-butyl sulfonamide 27 followed by removal of the tert-butyl group in refluxing trifluoroacetic acid (TFA). However, the final deprotection step of 26 proceeds very slowly on larger scale and is therefore time consuming. Finally, commercially available saccharin 27 and 6-bromosaccharin 28 were converted to their corresponding sodium salts using NaOMe in MeOH and were further subjected to an alkylation with a variety of alkyl halides containing different terminal heterofunctionalities and aryl groups (31a-d, 32a-f).
Physicochemical evaluation
In this study we attained scaffold analogues with an improved physicochemical profile (Supporting Information, Table S1 ). The computed physicochemical properties (molecular weight, clogP, PSA, HBD, HBA) of the new derivatives conformed with Lipinski's rule of five. Even though we maintained the highly lipophilic substitution pattern required to assure a minor loss in inhibitory activity 1,2 a clear improvement in polarity can be seen in the increase in PSA and the number of HBD and HBA. Derivatives based on the bicyclic sulfonamides (B-D) and saccharins (E) showed at a least twofold increase in PSA and a decrease by one unit in clogP compared to active chroman-4one based derivatives (e.g. 1-3).
Biological evaluation
The synthesized compounds were evaluated in a fluorescence-based assay for their inhibitory activity against SIRT2 at a compound concentration of 200 µM. 2, 20 The most active derivatives from each scaffold class were also tested for their inhibitory effect on SIRT1 and SIRT3 to investigate their selectivity towards the SIRT2-isoform. The results are summarized in Tables 1-3 .
The quinolone-4-(1H)-one series ( Table 1) resembles chromone in which the oxygen in the 1-position is replaced with a hydrogen bond donating NH-group. The evaluation of the inhibitory effect towards SIRT2 showed that similar biological effects cannot be achieved in this series despite its structural similarity to the chromone scaffold (Table 1) .
Further, as summarized in Table 2 , we tested various analogues based on bicyclic sulfonamide scaffolds B-D substituted with aliphatic groups (butyl, pentyl, phenethyl) in the 3-position as well as the bulkier 2-quinolinone group (18d). The mono-brominated bicyclic sulfonamides 15c and 15d based on scaffold B (Table 2 ) displayed only poor inhibitory activity with the phenethyl derivative 15d being the most active (35% inhibition at 200 µM concentration). Compared to nonbrominated 15a and b, introduction of the Br-group had only a marginal effect on the inhibitory activity as compared to the corresponding effect among the chroman-4-ones. 1 The di-brominated derivatives 18a-d based on the saturated bicyclic sulfonamide core structure C showed increased activity compared to 15c-d. Compound 18d was the most potent compound of the benzothiadiazine-1,1-dioxides with 74% inhibition of SIRT2. The unsaturated analogues 21a-c were considerably less potent (10-24% inhibition) with inhibitory activities in the range with the non-halogenated analogues based on scaffold B. Moreover, 21a-c showed very low solubility in most solvents and were therefore not considered for future optimization. The last scaffold evaluated in the study was the saccharin core, i.e. compounds 31a-d and 32a-f. As shown in Table 3 , derivatives based on this core structure showed only a minimal inhibitory effect, 31a and 31b as most active showed 34% at 200 µM concentration. For this series, the introduction of a bromide in the aromatic ring (32a-f) did not improve the activity.
Structure-activity relationship and molecular modeling
In order to investigate and get a better understanding of the observed SAR among these new series of compounds molecular modeling and docking studies were performed. For the docking trials we used our 3D model of SIRT2 which was previously used for docking studies of the corresponding chromones and chroman-4-ones. 2 The docking was performed using Glide with the OPLS3 force field 21 as implemented in the Schrödinger software. 22 OPLS3 is superior in predicting protein-ligand binding energy to commonly used force fields (e.g. OPLS_2005 and MMFF) 23, 24 and it is also parametrized to predict the geometry and energy contribution of aryl halogen bonds more accurately. 25 In the docking procedure the SIRT2 3D-structure was kept rigid while the ligands were flexible. A representative compound from each scaffold series was included together with a set of relevant previously published structurally analogous chroman-4-ones as reference ligands. Docking scores obtained from representative compounds of each compound class were compared (Supporting Information, Table  S2 ). The rank of the docking scores was in good agreement with the decreasing inhibitory activity from the most potent chroman-4-one (3) to the saccharins comprising the least active series of the new analogues.
As illustrated in Fig. 2 , docking studies of quinolone-4-(1H)-one 10b revealed a similar binding mode as observed for the chroman-4-ones/ chromones with the presence of the key enzyme/inhibitor interactions (see Fig. 1 ) such as the halogen bond and the hydrogen bond-interaction as well as the π-π interactions. However, in the suggested binding mode of this scaffold the polar NH-group of the quinolone-4-(1H)-ones is unfavourably positioned in a hydrophobic region close to Leu103 and 138 ( Fig. 2 ). This in turn, might explain the decrease in inhibitory The key enzyme/inhibitor interactions are present, i.e. the halogen bond to His187, the hydrogen bond to W1, and the π-π interaction to Phe96. The NH moiety in 10b is positioned in a hydrophobic region, close to two leucine residues (Leu103 and Leu138). The hydrophilic (purple) and hydrophobic (green) regions are highlighted on the surface of the binding site. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
activity.
The docking trial of the bicyclic sulfonamide scaffolds B-D revealed that they adopt similar binding poses as that observed for the parent scaffold. When looking at the binding pose of 15d and 18d as representative structures ( Fig. 3A and B) in the SIRT2 homology model, the Br-group in the 7-position (corresponding to 6-position of the chroman-4-ones) forms the expected halogen-bond with a backbone carbonyl group of SIRT2. The other Br-group of the dibrominated derivatives ( Fig. 3B) is buried in the hydrophobic pocket. The SO 2 NHgroup is placed in close proximity of a hydrogen bonding network comprising Ser88, His149, Thr166, Asn168, Asp170, Glu173 and a structural water molecule (W2) (see Fig. 3A ), this network is highly conserved throughout the sirtuin family. The sulfonyl interacts with the protein via a hydrogen bond of one of the sulfonyl oxygens with W1, while the second oxygen is positioned in close proximity to Asp170 (3.9 Å) as shown in Fig. 3A and B. This results in an electrostatic repulsion as the side-chain conformation of the aspartate is rotationally restricted due to its participation in the conserved hydrogen bonding network. The distance between the sulfonyl oxygen atom and Asp170 (3.9 Å) is also considerably shorter as compared to that between the carbonyl oxygen of 2 and Asp170 (5.5 Å, Fig. 3C ). The electrostatic repulsion could be the main contributor to the overall decreased inhibitory activity observed for scaffolds B-D as compared to the chroman-4-ones/chromones. In addition, a certain degree of flexibility in the scaffold might be required for reasonable binding to SIRT2 since derivatives 21a-c that are based on the more rigid scaffold D only showed negligible activity.
In general, derivatives based on the saccharin scaffold compose a series of only weak SIRT2 inhibitors with 34% inhibitory activity as the best (31a-b). Docking studies of this compound class revealed that they can adopt two different binding poses with either the sulfonyl group (Fig. 4A ) or the carbonyl moiety ( Fig. 4B) interacting with the structural water (W1) thereby mimicking the carbonyl group of the chroman-4-ones. Depending on the nature of the hydrogen bond interacting group, the mono-brominated compounds can additionally, either form the halogen bond ( Fig. 4A ) or the π-π-interaction with Phe96 ( Fig. 4B ).
In this series we observed an opposite trend in the inhibitory effect where the lack of the halogen substituents slightly increased the activity. The non-halogenated saccharin derivatives can bind closer to His187 thereby increasing the distance between the sulfonyl oxygen to the acidic Asp170 (4.8 Å). At the same time the carbonyl group is positioned further away from the lipophilic leucine residues Leu103 and Leu138 which could result in a more favourable binding mode which could explain the slight increase in inhibitory activity.
Conclusion
We have shown that bicyclic sulfonamides can act as scaffolds for SIRT inhibitors. The new scaffold analogues comprised a set of promising SIRT2 inhibitors (50-75% inhibition at 200 µM) with 18d, based on the sulfonamide scaffold C substituted with a 2-quinolinone containing alkyl group (Table 2) , being the most potent inhibitor identified in our study. Further optimization guided by molecular modeling will be performed around the benzothiadiazine-1,1-dioxides, to identify compounds that can be expected to be more potent.
Interestingly, two compounds (10b and 18b) show higher activity against SIRT3 than what we have previously seen for the chroman-4ones. This could be a potential starting point for the development of either more general SIRT inhibitors, so called pan inhibitors, or of more SIRT3 selective compounds.
Experimental
General information
All reactions were carried out using magnetic stirring under ambient atmosphere if not otherwise stated. Room temperature corresponds to a temperature interval from 20 to 22°C. All starting materials and reagents were obtained from commercial producers and were used without prior purification. Solvents were generally used as supplied by the manufacturer. Microwave reactions were carried out using a Biotage Initiator™ with fixed hold time modus in 0.5-2 mL, 2-5 mL or 10-20 mL capped microwave vials. All reactions were monitored by thin-layer chromatography (TLC) on silica plated aluminum sheets (Silica gel 60 F254, E. Merck). Spots were detected by UV light (254 or 365 nm). Purification by flash column chromatography was performed using an automatic Biotage SP4 Flash+® instrument. Prefabricated columns of different cartridge sizes (surface area 500 m 2 /g, porosity 60 Å, particle size 40-63 μm) were used. The NMR spectra were measured on a Varian 400-MR spectrometer or a 300 MHz instrument. 1 H and 13 
General procedure for the synthesis of β-ketoesters 8a-c
The carboxylic acid (1 equiv) and CDI (1.1 equiv) were dissolved in anhydrous THF (0.5 M) and stirred at room temperature for 1 h. Monomethyl potassium malonate 6 (1.2 equiv) and anhydrous MgCl 2 (1.5 equiv) were added and the reaction was stirred at room temperature overnight. The reaction was treated with 1 M HCl (aq). The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with water and brine, dried over Na 2 SO 4 , filtered and concentrated under reduced pressure. Purification by flash column chromatography (2 → 22% EtOAc in pentane) afforded β-ketoesters 8a-c. All 1 H NMR spectra also showed trace amounts of the enol tautomer of the product. Methyl 3-oxooctanoate (8a) . The compound was synthesized according to the general procedure from 7a (1.39 g, 12.0 mmol) to afford 8a (1.53 g, 74%) as a colourless oil. 1 Methyl 7-methoxycarbonyl-3-oxooctanoate (8c). The compound was synthesized according to the general procedure from 7c (1.46 g, 13.8 mmol) to afford 8c as a colourless oil (1.51 g, 77%). 1 H NMR (300 MHz) δ 3.74 (s, 3H), 3.67 (s, 3H), 3.45 (s, 2H), 2.57 (t, J = 6.9 Hz, 2H), 2.33 (t, J = 7.1 Hz, 2H), 1.69-1.58 (m, 4H). 13 
General procedure for the synthesis of 4-quinolones 10a-c
β-Ketoester (1 equiv), 2-bromo-4-chloroaniline (1.2 equiv) and p-TSA (0.1 equiv) were stirred in a sealed reaction vessel at 50°C for approximately 48 h. The mixture was transferred to a flask and refluxed briefly in cyclohexane. The solid was filtered off and the solvent was evaporated. The residue was dissolved in diphenyl ether (5 mL) and the solution was heated in a microwave reactor at 250°C for 45 min. Excess hexane was added and the product was collected the next day by filtration. The compounds were recrystallized from chloroform/hexane to remove traces of diphenyl ether. Bromo-6-chloro-2-pentylquinolin-4(1H)-one (10a) . The compound was synthesized according to the general procedure from 8a (544 mg, 3.87 mmol) to afford 10a (255 mg, 25%) as a brown solid. 1 13 
8-
2-Benzyl-8-bromo-6-chloroquinolin-4(1H)-one (10b).
The compound was synthesized according to the general procedure from 8b (322 mg, 1.68 mmol) to afford 10b (143 mg, 25%) as a brown solid. 1 
2-Iodobenzenesulfonamide (12)
To a suspension of 2-aminobenzenesulfonamide 11 (1.5 g, 8.71 mmol) in H 2 O/HCl (16:11 mL) cooled to 0°C was added a solution of NaNO 2 (0.91 g, 13.2 mmol) in H 2 O (16 mL). The mixture was stirred until a clear yellow solution was formed. A solution of KI (4.34 g, 26.1 mmol) in H 2 O (16 mL) was added and the red coloured mixture was heated to 90°C for 4 h. The mixture was allowed to cool to room temperature and the formed solid was filtered off, washed with water and pentane and dried under vacuum to afford 12 (1.65 g, 63%) as a light brown solid. 1 
5-Bromo-2-iodobenzenesulfonamide (13)
2-Iodobenzenesulfonamide 12 (846 mg, 2.99 mmol) was suspended in conc. H 2 SO 4 (20 mL) and warmed to 60°C. N-Bromosuccinimde (638 mg, 3.59 mmol) was added in one portion and the mixture was stirred at 60°C for 24 h. The mixture was poured on ice and the formed precipitate was filtered off, washed with water and pentane and dried in vacuo to afford 13 (941 mg, 87%) as off-white solid. 1 (br s, 2H), 7.49 (dd, J = 8.3, 2.3 Hz, 1H). 13 
General procedure for synthesis of alkyne derivatives 14a-c
To a vial with the appropriate 2-iodobenzenesulfonamide (1 equiv), Pd(PPh 3 ) 2 Cl 2 (0.1 equiv) and CuI (0.1 equiv) was added DMF (0.2 M) and Et 3 N (10 equiv) and the mixture was purged with N 2 gas. The appropriate alkyne (1.5 equiv) was added and the reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and filtered through Celite™. The organic phase was washed with 0.1 M HCl, water (3 × ) and brine (2 × ), dried over MgSO 4 , filtered and concentrated under reduced pressure. The crude product was purified by automated flash column chromatography (15%→20% EtOAc/pentane) to afford the desired products. -1-yn-1-yl)benzenesulfonamide (14a) The compound was synthesized according to the general procedure from 12 (400 mg, 1.40 mmol), Purification by automated flash column chromatography (0 → 45% EtOAc/pentane) to afford 14a (224 mg, 67%) as a white solid. 1 13 
2-(Hex
2-(4-Phenylbut-1-yn-1-yl)benzenesulfonamide (14b)
The compound was synthesized according to the general procedure from 12 (400 mg, 1.40 mmol), Purification by automated flash column chromatography (0 → 45% EtOAc/pentane) to afford 14b (309 mg, 77%) as a yellow solid. 1 5-Bromo-2-(hex-1-yn-1-yl)benzenesulfonamide (14c) The compound was synthesized according to the general procedure from 13 (108 mg, 0.30 mmol), Purification by automated flash column chromatography (0 → 30% EtOAc/pentane) to afford 14c (60 mg, 64%) as an off-white solid. 1 13 
5-Bromo-2-(4-phenylbut-1-yn-1-yl)benzenesulfonamide (14d)
The compound was synthesized according to the general procedure from 13 (105 mg, 0.29 mmol), Purification by automated flash column chromatography (0 → 40% EtOAc/pentane) to afford 14d (68 mg, 65%) as an off-white solid. 1 ). 13 
General procedure for synthesis of benzothiazine-1,1-dioxides 15a-d
A solution of the alkyne (1 equiv) in DMF (0.1 M) was added to a oven-dried MW vial containing KOH (4 equiv) and Pd(PPh 3 ) 2 OAc 2 (0.05 equiv). The mixture was heated to 60°C for 4.5-5 h. The mixture was diluted with EtOAc and washed with 1 M HCl (aq.), water and brine, dried over MgSO 4 , filtered and concentrated to afford the desire products after purification by automated flash column chromatography. Butyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15a) The compound was synthesized according to the general procedure from 14a (224 mg, 0.94 mmol). Purification by automated flash column chromatography (0 → 20% EtOAc/pentane) to afford 15a (95 mg, 42%) as a colourless oil that crystalizes over time. 1 13 
3-
3-Phenethyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15b)
The compound was synthesized according to the general procedure from 14b (309 mg, 1.08 mmol). Purification by automated flash column chromatography (0 → 20% EtOAc/pentane) to afford 15b (110 mg, 36%) as a yellow oil. 1 13 H, N.  7-Bromo-3-butyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15c) The compound was synthesized according to the general procedure from 14c (60 mg, 0.19 mmol). Purification by automated flash column chromatography (0 → 20% EtOAc/pentane) to afford 15c (15 mg, 25%) as a colourless oil that crystalizes over time. 1 ). 13 
7-Bromo-3-phenethyl-2H-benzo[e][1,2]thiazine 1,1-dioxide (15d)
The compound was synthesized according to the general procedure from 14c (68 mg, 0.19 mmol). Purification by automated flash column chromatography (0 → 20% EtOAc/pentane) to afford 15c (31 mg, 46%) as a colourless oil that crystalizes over time. 1 
2-Amino-3,5-dibromobenzenesulfonamide (16)
Br 2 (0.75 mL, 15 mmol) was added dropwise to a solution of 2aminobenzenesulfonamide 15 (1.01 g, 5.85 mmol) in DMF (4 mL) at < 10°C. The dark brown solution was stirred at 10-15°C for 15 min and then continued to stir at room temperature for 23 h. Additional Br 2 (0.15 mL, 2.9 mmol) was added and the stirring was continued at room temperature for 22 h. The mixture was diluted with EtOAc and treated with 10% Na 2 S 2 O 3 (aq.). After 10 min of stirring water was added, the phases were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with sat. Na 2 CO 3 (aq), water and brine, dried over MgSO 4 , filtered and concentrated under reduced pressure to afford 16 (1.96 g, > 99%) as a light-brown solid, which was directly used in the next step. 1 
General procedure for synthesis of saturated benzothiadiazine derivatives 18a-d
Compound 16 (1.1-1.2 equiv) and the appropriate aldehyde 17a-d (1 equiv) were dissolved in 4 M HCl in dioxane (0.04-0.06 M). The mixture was heated in a microwave reactor at 120°C for 1.5 h.
Work-up procedure A. The solvent was removed and the residue was diluted with EtOAc. The organic phase was washed with 2 M NaOH (aq), water, 0.1 M HCl (aq), water and brine, dried over MgSO 4 , filtered and concentrated under reduced pressure.
Work-up procedure B. The product was isolated by filtration and washed with EtOAc. 5,7-Dibromo-3-pentyl-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-1,1-dioxide (18a) . The compound was synthesized according to the general procedure from 16 (198 mg, 0.60 mmol), hexanal (17a, 0.05 mL, 0.50 mmol) and 4 M HCl in dioxane (10 mL). Work-up procedure A was used. Purification by flash column chromatography (10 → 20% EtOAc/pentane) and trituration with MeOH afforded 18a (106 mg, 51%) as a white solid. 1 5,7-Dibromo-3-phenethyl-3,4-dihydro-2H-benzo[e][1,2,4]thiadiazine-1,1-dioxide (18b) . The compound was synthesized according to the general procedure from 16 (200 mg, 0.61 mmol) and 17b (0.08 mL, 0.50 mmol). Work-up procedure A was used. Purification by flash column chromatography (10 → 20% EtOAc/pentane) and trituration with MeOH afforded 18b (117 mg, 53%) as an white solid. 1 -1,1-dioxide (18c) . The compound was synthesized according to the general procedure from 16 (89 mg, 0.27 mmol) and 17c (63 mg, 0.29 mmol) in a microwave reactor at 120°C for 1.5 h. Work-up procedure A was used. Purification by flash column chromatography (20 → 100% EtOAc/pentane) and recrystallization from MeCN afforded 18c (52 mg, 34%) as an off-white solid. 1 1,2,4]thiadiazine-1,1-dioxide (18d) . The compound was synthesized according to the general procedure from 16 (75 mg, 0.23 mmol) and 17d (42 mg, 0.21 mmol). Work-up procedure B was used and 18d (39 mg, 37%) was afforded as a light-brown solid. 1 
5,7-Dibromo-3-(3-bromophenethyl)-3,4-dihydro-2H-benzo[e] [1,2,4]thiadiazine
5,7-Dibromo-3-(2-(quinolin-2(1H)-one-6-yl)ethyl)-3,4-dihydro-2H-benzo[e][
General procedure for synthesis of unsaturated benzothiadiazine derivatives 21a-c
A solution of carboxylic acid (1.3 equiv) and CDI (1.2-1.8 equiv) in dry CH 2 Cl 2 (0.4-0.7 M) was stirred at room temperature for 1.5-4 h. Sulfonamide 16 (1 equiv) dissolved in dry CH 2 Cl 2 (0.4-0.5 M) and 15-50 vol% DMF was added and the solution was heated to reflux for 21 h. The solvent was removed and the residue was dissolved in a large quantity of EtOAc and washed with 0.1 M HCl (aq), sat. Na 2 CO 3 (aq) and brine, dried over MgSO 4 , filtered and concentrated under reduced pressure. The crude product was dissolved in EtOH, Cs 2 CO 3 (2 equiv) was added and the mixture was heated in a microwave reactor at 120°C for 1.5 h The solvent was removed and 1 M HCl (aq) was added. The formed precipitation was filtered off and washed with EtOAc. Dibromo-3-phenethyl-4H-benzo[e][1,2,4]thiadiazine-1,1-dioxide (21a) . The compound was synthesized according to the general procedure from 16 (373 mg, 1.13 mmol). Purification by recrystallization from MeCN afforded 21a (120 mg, 21% over two steps) as an off-white solid. 1 H NMR (DMSO-d 6 ) δ 7.98 (d, J = 2.4 Hz, 1H), 7.74 (d, J = 2.3 Hz, 1H), 7.31-7.20 (m, 4H), 7.14 (tt, J = 5.9, 3.0 Hz, 1H), 2.96 (m, 2H), 2.76 (t, J = 7.9 Hz, 2H). 13 5,7-Dibromo-3-(3-bromophenethyl)-3,4-dihydro-2H-benzo[e]  [1,2,4]thiadiazine-1,1-dioxide (21b) . The compound was synthesized according to the general procedure from 16 (251 mg, 0.76 mmol). Purification by recrystallization from MeCN afforded 21b (97 mg, 24% over two steps) as an off-white solid. 1 13 -1,1-dioxide (21c) . The compound was synthesized according to the general procedure from 16 (253 mg, 0.77 mmol). Purification by recrystallization from MeCN afforded 21c (146 mg, 37% over two steps) as an off-white solid. 1 
5,7-
5,7-Dibromo-3-(4-bromophenethyl)-3,4-dihydro-2H-benzo[e] [1,2,4]thiadiazine
5-Bromo-2-methylbenzenesulfonyl chloride (23)
A solution of ClSO 3 H (7.00 mL, 103 mmol) in CH 2 Cl 2 (12 mL) was added dropwise to an ice-cold solution of 4-bromotoluene (2.61 g, 15 mmol) in CH 2 Cl 2 (25 mL). The mixture was stirred in an ice-bath overnight, while the temperature increased to 10°C. The solvent was removed and the residue was added dropwise to ice-water. The formed solid was filtered off and washed with water to afford a mixture (3.85 g, 94%, 86:14 ratio according to 1 H NMR) of 23 (major isomer, 81%) and 2-bromo-5-methylbenzenesulfonyl chloride as a colourless oil. 1 
5-Bromo-2-methylbenzenesulfonamide (24)
To an ice cold solution of 23 (5.83 g, 21.6 mmol) in Et 2 O (100 mL) was added aqueous ammonia (25%, 20 mL). The mixture was refluxed for 2 h and finally stirred at room temperature for 48 h. The solvent was removed under reduced pressure and the formed solid was filtered off, extensively washed with water and dried in vacuo to afford a mixture (5.29 g, 98%, 83:17 ratio according to 1 H NMR signal of CH 3 -group) of 24 (major isomer, 81%) and 2-bromo-5-methylbenzenesulfonamide (minor isomer, 17%) as a white solid. 1 A solution of 23 (7.06 g, 26.2 mmol) in dry CH 2 Cl 2 (60 mL) was dropwise added to a solution of tert-butylamine (2.88 mL, 27.5 mmol) and Et 3 N (3.83 mL, 27.5 mmol) in CH 2 Cl 2 (120 mL) at 0°C. The mixture was stirred at 0°C for 1.5 h, was then allowed to warm to room temperature and stirred at this temperature for 24 h. The mixture was washed with 0.1 M HCl (aq.) and sat. NaHCO 3 (aq.), dried over MgSO 4 , filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (17% EtOAc/pentane) to afford 25 (5.65 g, 70% yield, 23% of the other regioisomer). H 5 IO 6 (15.5 g, 68.0 mmol) was vigorously stirred in MeCN (85 mL) for 1 h. CrO 3 (254 mg, 2.55 mmol) and acetic anhydride (6.4 mL, 68.0 mmol) were added and the suspension was stirred for 10 min at room temperature. The mixture was cooled in an ice-bath and 25 (2.60 g, 8.49 mmol, ratio 77:23 according to 1 H NMR spectra) was added in one portion. The mixture was stirred at 0°C for 15 min and then allowed to warm to room temperature and stirred for 13 h. The solvent was removed and the remaining slurry was stirred in EtOAc (100 mL) for 10 min. The solid was filtered off, washed with EtOAc and acetone and the filtrate was concentrated under reduced pressure. Water was added and the aqueous phase was extracted with EtOAc. The combined organic phases were washed with sat. NaHCO 3 (aq), sat. Na 2 S 2 O 3 (aq) and brine, dried over MgSO 4 , filtered and concentrated under reduced pressure. The crude product was dissolved in TFA (20 mL) and heated to reflux for 48 h and thereafter stirred at room temperature for 4 d. The TFA was removed from the formed precipitate and concentrated under reduced pressure. The precipitate and the remaining solid after evaporation were treated with CH 2 Cl 2 , and dried in vacuo to afford 28 (1.14 g, 62% overall yield based on 25). 1 
General procedure for the synthesis of the sodium salt of saccharins (29 and 30)
To a 0.2 M solution of saccharin (1 equiv) in dry MeOH, NaOMe (1.01 equiv) was added and the mixture was stirred for 6 h at room temperature. The solvent was removed and the residue was dried in vacuo.
Sodium saccharin (29) . The compound was synthesized according to the general procedure from saccharin 27 (8.0 g, 44 mmol) to afford 29 (8.8 g, 98%) as a white solid which was directly used in the next step.
Sodium 6-bromosaccharin (30) . The compound was synthesized according to the general procedure from 28 (824 mg, 2.97 mmol) to afford 30 (896 mg, > 99%) as a white solid which was directly used in the next step.
General procedure for the alkyl substituted saccharins 31a-d and 32a-f
The sodium salts of saccharin 29 or 30 (1 equiv) was dissolved in DMF (1 M) and the appropriate halide (1.05 equiv) was added. The mixture was heated in a microwave reactor at 145°C for 1 h if not otherwise stated. The mixture was poured on ice-water and the precipitate was filtered off, washed with water and pentane and dried in vacuo. If no precipitate was formed, the aqueous phase was extracted with EtOAc and the combined organic phases were washed with brine, dried over MgSO 4 , filtered and concentrated under reduced pressure. -1,1-dioxide (31a) . The compound was synthesized according to the general procedure from 29 (150 mg, 0.731 mmol). Purification by flash column chromatography (40% EtOAc/pentane) afforded 31a (143 mg, 77%) as a colourless oil. 
2-Pentylbenzo[d]isothiazol-3(2H)-one
SIRT1-3 in vitro assay
The Fluor de Lys fluorescence assays were based on the method described in the BioMol product sheet (Enzo Life Sciences) using the BioMol KI177 substrate for SIRT1 and the KI179 substrate for SIRT2 and SIRT3. The determined K m value of SIRT1 for KI177 was 58 μM, and the K m of SIRT2 for KI179 was 198 μM. 26 The K m of SIRT3 for KI179 was reported by Enzo Life Sciences to be 32 μM. The K m values of SIRT1, SIRT2 and SIRT3 for NAD + were reported by BioMol to be 558 μM, 547 μM and 2 mM, respectively.
Briefly, assays were carried out using the Fluor de Lys acetylated peptide substrate at 0.7 K m and NAD + (Sigma N6522 or BioMol KI282) at 0.9 K m , recombinant GST-SIRT1/2-enzyme or recombinant His-SIRT3 and SIRT assay buffer (KI286). GST-SIRT1 and GST-SIRT2 were produced as described previously. 27, 28 His-SIRT3 (BML-SE270) was purchased from Enzo Life Sciences. The buffer, Fluor de Lys acetylated peptide substrate, NAD + and DMSO/compounds in DMSO (2.5 μL in 50 μL total reaction volume; DMSO from Sigma, D2650) were preincubated for 5 min at room temperature. The reaction was started by adding the enzyme. The reaction mixture was incubated for one hour at 37°C. After that, Fluor de Lys developer (KI176) and 2 mM nicotinamide (KI283) in SIRT assay buffer (total volume 50 μL) were added, and the incubation was continued for 45 min at 37°C. Fluorescence readings were obtained using EnVision 2104 Multilabel Reader (Perki-nElmer) with excitation wavelength 370 nm and emission 460 nm.
Molecular modeling
Docking
The previously published 3D-structure of SIRT2 2 was prepared using Protein Preparation Wizard 29 implemented in the Schrödinger Suite. Ensembles of conformations for each ligand to be docked were generated in order to prevent the starting conformation bias the final docking solutions. In case of a chiral compound, both enantiomers were docked. The docking was conducted using Glide XP (extra precision) into the proposed binding site for the chroman-4-one inhibitors. 2 In the docking trial the protein structure was held rigid while the ligands were flexible. The best scored docking solutions that fulfilled the inhibitorenzyme key interactions were reported. Single point energies for each docked ligand conformation were calculated, to be able to determine their relative energies. All calculations have been performed using OPLS3 force field 21 in a water solvation model with tools implemented in Schrödinger Suite. 22
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